secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2024-02-16T23:59:59+00:00
Accession:  0001140361-24-008352
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocuphire Pharma appoints Nirav Jhaveri as CFO and Ash Jayagopal as Chief Scientific Officer
--------------------------------------------------------------------------------

- Nirav Jhaveri appointed CFO effective Feb 12, 2024; base salary $410k, equity awards: 210k options + 140k RSUs.
- Ash Jayagopal appointed Chief Scientific and Development Officer; 15+ years retinal disease experience, previously at Opus Genetics and Roche.
- Jhaveri previously CFO at Insilico Medicine and Journey Medical; over 20 years biopharma finance experience.
- Both appointments effective Feb 12, 2024, as company advances APX3330 phase 3 in diabetic retinopathy.
- Jhaveri eligible for discretionary annual cash bonus up to 45% of base salary; severance includes 0.75x salary plus prorated bonus.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036124008352/0001140361-24-008352-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036124008352/ef20021883_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-008352

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer